BOSTON, June 30, 2021 /PRNewswire/ — Medisafe, a leading digital drug companion company, today announced the findings from two validation studies examining the impact of its digital drug companion on persistence to specialty medications (Rx). Led by Komodo Health, the analysis used real-world patient data to examine the impact of digital drug companions to influence patient engagement. The finding indicates that specialty medicine patients extended persistence by 15%, and improved adherence by 7% among patients pre- vs. post-Medisafe start.

Read more here.